Novel, innovative, and targeted medicines to improve outcomes for cancer patients
Previous studies have shown that modulating IL-21 activity can enhance immunotherapy
Pio Therapeutics is developing a first-in-class agonistic antibody to IL-21
to IL-21 for oncology
Validated in vitro functional assays
Robust IP portfolio
Proof of concept data
with in vivo preclinical models
Defined toxicology and regulatory pathway
Clear application to oncology as an unmet medical need
Amplifying success in immunotherapy
When harnessed appropriately, the immune system is an extremely potent and specific endogenous anti-tumour mechanism. Our first-in-class agonist antibody has been designed to address current clinical challenges associated with immunotherapy such as improving the rate and quality of responses, while also addressing the clinical challenges that have been encountered with recombinant IL-21.
Novel, innovative, targeted medicines
Our mission is to develop novel, innovative and targeted medicines that augment endogenous anti-tumour immunity to further improve outcomes for patients affected by cancer.
Pio Tx’s team brings decades of global scientific and commercial expertise, with proven success in therapeutic discovery, preclinical, clinical, regulatory and commercial stages of drug development.
MD PhD FRACS MBA
Chief Executive Officer & Managing Director
Chief Scientific Officer
BSc Grad Cert BA
Chief Operating Officer & Company Secretary
Immunotherapy has revolutionised cancer treatment, however there are challenges to its efficacy.
Pio Tx is developing a selective agonistic anti-IL-21 monoclonal antibody that has been designed to amplify the bioactivity of endogenously produced IL-21, proportional to its localized expression. This approach will overcome clinical challenges associated with recombinant IL-21, take advantage of an antibody as a therapeutic modality, and allow combinatorial approaches with other therapeutics to be easily developed.